Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor.

Wu J, Li W, Craddock BP, Foreman KW, Mulvihill MJ, Ji QS, Miller WT, Hubbard SR.

EMBO J. 2008 Jul 23;27(14):1985-94. doi: 10.1038/emboj.2008.116. Epub 2008 Jun 19.


A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.

Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA.

Mol Cancer Ther. 2007 Aug;6(8):2158-67. Epub 2007 Aug 1.


Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.

Zeng X, Zhang H, Oh A, Zhang Y, Yee D.

Breast Cancer Res Treat. 2012 May;133(1):117-26. doi: 10.1007/s10549-011-1713-x. Epub 2011 Aug 18.


Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.

Logan JG, Sophocleous A, Marino S, Muir M, Brunton VG, Idris AI.

J Bone Miner Res. 2013 May;28(5):1229-42. doi: 10.1002/jbmr.1847.


Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.

Favelyukis S, Till JH, Hubbard SR, Miller WT.

Nat Struct Biol. 2001 Dec;8(12):1058-63.


The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.

Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S.

Clin Cancer Res. 2010 Nov 15;16(22):5436-46. doi: 10.1158/1078-0432.CCR-10-2054. Epub 2010 Oct 13.


Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.

Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR.

Mol Cancer Ther. 2010 Oct;9(10):2652-64. doi: 10.1158/1535-7163.MCT-10-0318. Epub 2010 Oct 5.


Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation.

Pautsch A, Zoephel A, Ahorn H, Spevak W, Hauptmann R, Nar H.

Structure. 2001 Oct;9(10):955-65.


Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.

Mulvihill MJ, Ji QS, Coate HR, Cooke A, Dong H, Feng L, Foreman K, Rosenfeld-Franklin M, Honda A, Mak G, Mulvihill KM, Nigro AI, O'Connor M, Pirrit C, Steinig AG, Siu K, Stolz KM, Sun Y, Tavares PA, Yao Y, Gibson NW.

Bioorg Med Chem. 2008 Feb 1;16(3):1359-75. Epub 2007 Oct 23.


Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.

Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN.

AAPS J. 2012 Mar;14(1):1-9. doi: 10.1208/s12248-011-9308-3. Epub 2011 Nov 19.


1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors.

Mulvihill MJ, Ji QS, Werner D, Beck P, Cesario C, Cooke A, Cox M, Crew A, Dong H, Feng L, Foreman KW, Mak G, Nigro A, O'Connor M, Saroglou L, Stolz KM, Sujka I, Volk B, Weng Q, Wilkes R.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):1091-7. Epub 2006 Nov 10.


Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.

Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG.

Cancer Res. 2008 Oct 1;68(19):8004-13. doi: 10.1158/0008-5472.CAN-08-0280.


Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS.

Cancer Res. 2008 Oct 15;68(20):8322-32. doi: 10.1158/0008-5472.CAN-07-6720.


Inhibition of insulin-like growth factor I receptor tyrosine kinase by ethanol.

Rubin R, Harrison R, Chen XF, Corzitotto J, Hoek JB, Hallak H.

Biochem Pharmacol. 2004 Nov 15;68(10):2009-17.


Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, Gao MY, Hua S, Chen C, Kim S, Michellys PY, Lesley SA, Harris JL, Spraggon G.

Biochem J. 2010 Sep 15;430(3):425-37. doi: 10.1042/BJ20100609.


Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity.

Munshi S, Kornienko M, Hall DL, Reid JC, Waxman L, Stirdivant SM, Darke PL, Kuo LC.

J Biol Chem. 2002 Oct 11;277(41):38797-802. Epub 2002 Jul 22.


The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity.

Lou M, Garrett TP, McKern NM, Hoyne PA, Epa VC, Bentley JD, Lovrecz GO, Cosgrove LJ, Frenkel MJ, Ward CW.

Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12429-34. Epub 2006 Aug 7.


Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors.

Tong LJ, Xie H, Peng T, Liu XF, Xin XL, Huang X, Chen SM, Liu HY, Li HL, Geng MY, Yin M, Ding J.

Acta Pharmacol Sin. 2011 Jul;32(7):930-8. doi: 10.1038/aps.2011.23. Epub 2011 Jun 6.


Extracellular vimentin interacts with insulin-like growth factor 1 receptor to promote axonal growth.

Shigyo M, Kuboyama T, Sawai Y, Tada-Umezaki M, Tohda C.

Sci Rep. 2015 Jul 14;5:12055. doi: 10.1038/srep12055.

Supplemental Content

Support Center